Novozymes maintains investment plans despite pandemic

Covid-19 has thus far not impacted Novozymes' willingness to invest, the group's CFO says. The underlying growth and potential remain intact.

Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY EMMA GELBJERG-HANSEN, CLEANTECHWATCH

Even though some of enzyme producer's investment plans were delayed due to the Covid-19 pandemic, Novozymes Chief Financial Officer Lars Green is not worried about the future, he tells Danish business media Finans in an interview.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    On June 1, Senvion's former CFO Manav Sharma started as US country manager for Nordex. Soon he will have a new factory at his disposal. | Foto: Senvion

    Nordex restarts production in the US

    For subscribers

    Further reading